MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 325.72 ($4.36) and traded as low as GBX 295.50 ($3.96). MaxCyte shares last traded at GBX 302 ($4.04), with a volume of 3,510 shares traded.
MaxCyte Stock Performance
The firm’s 50 day simple moving average is GBX 324.04 and its 200-day simple moving average is GBX 334.08. The company has a market capitalization of £308.96 million, a PE ratio of -1,119.23 and a beta of 1.13. The company has a quick ratio of 14.38, a current ratio of 14.31 and a debt-to-equity ratio of 8.37.
MaxCyte Company Profile
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Stories
- Five stocks we like better than MaxCyte
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- What is the Nikkei 225 index?
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- About the Markup Calculator
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
